About the study medicine
Pfizer is investigating a study medicine, PF-08634404, which is a bispecific antibody that was designed to target both PD-1 and VEGF to potentially block immune checkpoints and inhibit angiogenesis. This dual mechanism has the potential to achieve tumor immunosurveillance, while disrupting vascular support for tumor progression, compared with blocking either target alone in patients with solid tumors.
The study medicine is currently being studied in various cancer types, including lung, colorectal, urothelial, renal, hepatocellular carcinomas, gastric, gastroesophageal junction and esophageal carcinomas, and endometrial cancer.
The Symbiotic clinical trials
Explore Pfizer’s Symbiotic program, which is a series of clinical trials evaluating a novel investigational bispecific antibody that is designed to target both PD-1 and VEGF.
A Phase 3 clinical trial evaluating PF-08634404 combined with chemotherapy or pembrolizumab combined with chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer in your patients who are not candidates for surgical resection and curative concurrent/sequential chemoradiotherapy.
A Phase 3 clinical trial evaluating PF-08634404 or bevacizumab combined with chemotherapy in your patients with metastatic colorectal cancer who have not received prior systemic treatment for metastatic disease.
A Phase 1b/2 clinical trial of PF-08634404 as monotherapy or in combination with enfortumab vedotin for your patients with unresectable, locally advanced, or metastatic urothelial cancer. The clinical trial includes participants previously treated and those previously untreated for locally advanced or metastatic urothelial cancer.
A Phase 1b/2 clinical trial of PF-08634404 as monotherapy and combination therapy with ipilimumab or axitinib for your patients with locally advanced or metastatic renal cell carcinoma who have received no previous systemic therapy for RCC.
A Phase 2 clinical trial evaluating PF-08634404 as monotherapy or in combination regimens as neoadjuvant, adjuvant, and consolidation therapy for your patients with early-stage resectable or locally advanced unresectable NSCLC, regardless of disease histology.